240 related articles for article (PubMed ID: 29251581)
21. The efficacy of febuxostat and allopurinol in the treatment of gout with hyperuricemia.
Wang S
Pak J Pharm Sci; 2018 Jul; 31(4(Special)):1623-1627. PubMed ID: 30203749
[TBL] [Abstract][Full Text] [Related]
22. Placebo-controlled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in japan: late phase 2 clinical study.
Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S35-43. PubMed ID: 21654268
[TBL] [Abstract][Full Text] [Related]
23. Comparison of the efficacy and safety of benzbromarone and febuxostat in gout and hyperuricemia: a systematic review and meta-analysis.
Wu F; Chen L; Du Y
Clin Rheumatol; 2024 May; 43(5):1745-1754. PubMed ID: 38492092
[TBL] [Abstract][Full Text] [Related]
24. Study of therapeutic efficacy of febuxostat in chronic kidney disease stage IIIA to stage VD.
Sarvepalli PS; Fatima M; Quadri AK; Taher AR; Habeeb A; Amreen F; Parveen BN; Rajaram KG
Saudi J Kidney Dis Transpl; 2018; 29(5):1050-1056. PubMed ID: 30381500
[TBL] [Abstract][Full Text] [Related]
25. Comparative effectiveness of allopurinol, febuxostat and benzbromarone on renal function in chronic kidney disease patients with hyperuricemia: a 13-year inception cohort study.
Chou HW; Chiu HT; Tsai CW; Ting IW; Yeh HC; Huang HC; Kuo CC;
Nephrol Dial Transplant; 2018 Sep; 33(9):1620-1627. PubMed ID: 29165620
[TBL] [Abstract][Full Text] [Related]
26. Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
Becker MA; Schumacher HR; Wortmann RL; MacDonald PA; Eustace D; Palo WA; Streit J; Joseph-Ridge N
N Engl J Med; 2005 Dec; 353(23):2450-61. PubMed ID: 16339094
[TBL] [Abstract][Full Text] [Related]
27. Effects of Febuxostat on Oxidative Stress.
Fukui T; Maruyama M; Yamauchi K; Yoshitaka S; Yasuda T; Abe Y
Clin Ther; 2015 Jul; 37(7):1396-401. PubMed ID: 25913922
[TBL] [Abstract][Full Text] [Related]
28. Placebo-controlled, double-blind study of the non-purine-selective xanthine oxidase inhibitor Febuxostat (TMX-67) in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.
Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S19-26. PubMed ID: 21654266
[TBL] [Abstract][Full Text] [Related]
29. Randomized, Open-Label, Cross-Over Comparison of the Effects of Benzbromarone and Febuxostat on Endothelial Function in Patients with Hyperuricemia.
Nakata T; Ikeda S; Koga S; Yonekura T; Tsuneto A; Doi Y; Fukae S; Minami T; Kawano H; Maemura K
Int Heart J; 2020 Sep; 61(5):984-992. PubMed ID: 32921665
[TBL] [Abstract][Full Text] [Related]
30. Effect of allopurinol on slowing allograft functional decline in kidney transplant recipients.
Osadchuk L; Bashir MH; Tangirala B; Marcus RJ; Nashar K; Hussain SM; Sureshkumar KK
Exp Clin Transplant; 2014 Jun; 12(3):190-4. PubMed ID: 24907717
[TBL] [Abstract][Full Text] [Related]
31. Safety and Efficacy of Benzbromarone and Febuxostat in Hyperuricemia Patients with Chronic Kidney Disease: A Prospective Pilot Study.
Yu H; Liu X; Song Y; Cheng J; Bao H; Qin L; Zhou X; Wang L; Peng A
Clin Exp Nephrol; 2018 Dec; 22(6):1324-1330. PubMed ID: 29761242
[TBL] [Abstract][Full Text] [Related]
32. The Association of Febuxostat Compared With Allopurinol on Blood Pressure and Major Adverse Cardiac Events Among Adult Patients With Hyperuricemia: A Meta-analysis.
Barrientos-Regala M; Macabeo RA; Ramirez-Ragasa R; Pestaño NS; Punzalan FER; Tumanan-Mendoza B; Castillo RR
J Cardiovasc Pharmacol; 2020 Oct; 76(4):461-471. PubMed ID: 32675751
[TBL] [Abstract][Full Text] [Related]
33. Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients with chronic kidney disease (NU-FLASH trial for CKD).
Sezai A; Soma M; Nakata K; Osaka S; Ishii Y; Yaoita H; Hata H; Shiono M
J Cardiol; 2015 Oct; 66(4):298-303. PubMed ID: 25649025
[TBL] [Abstract][Full Text] [Related]
34. Safety and efficacy of oral febuxostat for treatment of HLA-B*5801-negative gout: a randomized, open-label, multicentre, allopurinol-controlled study.
Yu KH; Lai JH; Hsu PN; Chen DY; Chen CJ; Lin HY
Scand J Rheumatol; 2016 Jul; 45(4):304-11. PubMed ID: 26771445
[TBL] [Abstract][Full Text] [Related]
35. Renoprotective effects of febuxostat in hyperuricemic patients with chronic kidney disease: a parallel-group, randomized, controlled trial.
Tanaka K; Nakayama M; Kanno M; Kimura H; Watanabe K; Tani Y; Hayashi Y; Asahi K; Terawaki H; Watanabe T
Clin Exp Nephrol; 2015 Dec; 19(6):1044-53. PubMed ID: 25676011
[TBL] [Abstract][Full Text] [Related]
36. Previous Dosage of Allopurinol Is a Strong Determinant of Febuxostat Efficacy.
Koide H; Hira D; Tsujimoto M; Katsube Y; Minegaki T; Uzu T; Ikeda Y; Morita SY; Nishiguchi K; Terada T
Biol Pharm Bull; 2017; 40(5):681-686. PubMed ID: 28458354
[TBL] [Abstract][Full Text] [Related]
37. Effect of Febuxostat on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension: A Phase 2 Randomized Placebo-Controlled Study.
Gunawardhana L; McLean L; Punzi HA; Hunt B; Palmer RN; Whelton A; Feig DI
J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29102979
[TBL] [Abstract][Full Text] [Related]
38. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
Schumacher HR; Becker MA; Wortmann RL; Macdonald PA; Hunt B; Streit J; Lademacher C; Joseph-Ridge N
Arthritis Rheum; 2008 Nov; 59(11):1540-8. PubMed ID: 18975369
[TBL] [Abstract][Full Text] [Related]
39. Febuxostat for the chronic management of hyperuricemia in patients with gout.
Chinchilla SP; Urionaguena I; Perez-Ruiz F
Expert Rev Clin Pharmacol; 2016; 9(5):665-73. PubMed ID: 26942273
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of febuxostat for treatment of asymptomatic hyperuricemia among kidney transplant patients: A meta-analysis of observational studies.
Chewcharat A; Chang YT; Thongprayoon C; Crisafio A; Bathini T; Mao MA; Cheungpasitporn W
Clin Transplant; 2020 Apr; 34(4):e13820. PubMed ID: 32034944
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]